|
US6184024B1
(en)
|
1988-07-14 |
2001-02-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Chimeric and/or growth-restricted flaviviruses
|
|
US6190859B1
(en)
|
1995-04-17 |
2001-02-20 |
The United States Of America As Represented By The Secretary Of The Army |
Method and kit for detection of dengue virus
|
|
US6254873B1
(en)
|
1995-04-17 |
2001-07-03 |
The United States Of America As Represented By The Secretary Of The Army |
Inactivated dengue virus vaccine
|
|
WO1996040933A1
(en)
|
1995-06-07 |
1996-12-19 |
The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services |
Infectious dengue 2 virus pdk-53 as quadravalent vaccine
|
|
EP0836090A1
(en)
|
1996-10-12 |
1998-04-15 |
Evotec BioSystems GmbH |
Method of analysis of samples by determination of the distribution of specific brightnesses of particles
|
|
NZ337522A
(en)
|
1997-02-28 |
2001-02-23 |
St |
Chimeric flavivirus incorporating yellow fever virus modified such that a prM-E protein of a second flavivirus is expressed, and vaccines for flavivruses
|
|
JP2001511459A
(ja)
|
1997-07-31 |
2001-08-14 |
ハワイ バイオテクノロジー グループ， インコーポレイテッド |
フラビウイルス感染に対抗する組換え二量体エンベロープワクチン
|
|
CA2341354C
(en)
|
1998-09-02 |
2009-10-20 |
The Government Of The United States Of America |
Dengue viruses that are replication defective in mosquitos for use as vaccines
|
|
EP1165128A2
(en)
|
1999-03-26 |
2002-01-02 |
Walter Reed Army Institute of Research |
Attenuated dengue-2 virus vaccine
|
|
ES2322327T3
(es)
|
1999-03-26 |
2009-06-19 |
Walter Reed Army Institute Of Research |
Vacuna multivalente contra el virus del dengue.
|
|
AU4179200A
(en)
|
1999-03-26 |
2000-10-16 |
Walter Reed Army Institute Of Research |
Attenuated dengue-1 virus vaccine
|
|
WO2000057910A1
(en)
|
1999-03-26 |
2000-10-05 |
Walter Reed Army Institute Of Research |
Attenuated dengue-4 virus vaccine
|
|
US6432411B1
(en)
|
1999-07-13 |
2002-08-13 |
Hawaii Biotechnology Group |
Recombinant envelope vaccine against flavivirus infection
|
|
EP1402075B1
(en)
|
2001-05-22 |
2012-11-14 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, |
Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
|
|
AU2003267937C1
(en)
|
2002-01-15 |
2019-08-08 |
Sanofi Pasteur Biologics, Llc |
Flavivirus vaccines
|
|
DK2338508T3
(en)
*
|
2002-05-03 |
2018-05-28 |
The Government Of The Us Secretary Department Of Health And Human Services |
rDEN3 / 4delta30 (ME), rDEN2 / 4delta30 (ME) or rDEN1 / 4delta30 (ME) recombinant chimeric Dengue virus containing a 30 nucleotide deletion (delta30) in a section of the 3 'untranslated region of Dengue type 4 genome, where The 30-nucleotide deletion corresponds to the TL2 hairpin structure
|
|
WO2003101397A2
(en)
|
2002-05-31 |
2003-12-11 |
Acambis, Inc. |
Tetravalent dengue vaccines
|
|
US7189403B2
(en)
|
2003-06-30 |
2007-03-13 |
Institut Pasteur |
Attenuated flavivirus strains containing a mutated M-ectodomain and their applications
|
|
EP1699814A4
(en)
|
2003-12-08 |
2009-01-14 |
Hybridon Inc |
MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF COMPOUNDS FORMED FROM SMALL OLIGONUCLEOTIDES
|
|
US8029802B2
(en)
|
2004-10-20 |
2011-10-04 |
Sanofi Pasteur Biologics Co. |
Vaccines against Japanese encephalitis virus and West Nile virus
|
|
ATE475706T1
(de)
|
2005-06-17 |
2010-08-15 |
Sanofi Pasteur |
Abgeschwächter dengue-serotyp-2-stamm
|
|
CA2611934C
(en)
|
2005-06-17 |
2015-11-03 |
Sanofi Pasteur |
Dengue serotype 1 attenuated strain
|
|
CN101222936A
(zh)
|
2005-06-24 |
2008-07-16 |
英特威国际有限公司 |
灭活的嵌合疫苗和相关的使用方法
|
|
US8017754B2
(en)
|
2005-07-22 |
2011-09-13 |
Research Development Foundation |
Attenuated virus strains and uses thereof
|
|
US7470674B2
(en)
|
2005-11-07 |
2008-12-30 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
|
AR061197A1
(es)
|
2006-06-07 |
2008-08-13 |
Sanofi Pasteur |
Cepas del virus 3 del dengue vivas atenuadas
|
|
PL2589602T3
(pl)
*
|
2006-08-15 |
2016-11-30 |
|
Rozwinięcie komponentów szczepionki przeciwko wirusowi dengi
|
|
FR2906724B1
(fr)
|
2006-10-04 |
2009-03-20 |
Sanofi Pasteur Sa |
Methode d'immunisation contre les 4 serotypes de la dengue.
|
|
WO2008127307A2
(en)
|
2006-11-09 |
2008-10-23 |
The United States Of America As Represented By The Secretary Of The Navy |
Induction of an immune response against dengue virus using prime-boost approach
|
|
US8440202B2
(en)
|
2006-11-09 |
2013-05-14 |
The United States Of America As Represented By The Secretary Of The Navy |
Induction of an immune response against dengue virus using the prime-boost approach
|
|
BRPI0904020B8
(pt)
*
|
2009-10-01 |
2021-05-25 |
Fundacao Oswaldo Cruz |
composição vacinal contra o vírus da dengue, e, kit
|
|
MY166534A
(en)
|
2010-10-29 |
2018-07-10 |
Merck Sharp & Dohme |
Recombinant subunit dengue virus vaccine
|
|
WO2012065105A2
(en)
*
|
2010-11-12 |
2012-05-18 |
Thomas Monath |
Chimeric flavivirus vaccines
|
|
PE20150356A1
(es)
*
|
2012-07-24 |
2015-03-20 |
Sanofi Pasteur |
Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
|
|
JP2016523251A
(ja)
|
2013-06-21 |
2016-08-08 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
デングウイルスワクチン組成物およびその使用方法
|